Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Monkhorst

Showing results (41-50 of 103) with videos related to

Pageof 11
Sort By:
JCO Precision Oncology|October 11, 2021
Clinical Utility of Plasma-Based Comprehensive Molecular Profiling in Advanced Non-Small-Cell Lung CancerRobert D Schouten, Daan C L Vessies, Linda J W Bosch, et al.
ERJ Open Research|March 29, 2019
Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisionsKarlijn Hummelink, Mirte Muller, Theodora C Linders, et al.
Molecular Oncology|June 8, 2022
Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II-IIIA NSCLC patientsDaan C L Vessies, Milou M F Schuurbiers, Vincent van der Noort, et al.
Plos Medicine|April 15, 2025
Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: A retrospective validation studyMilou M F Schuurbiers, Christopher G Smith, Koen J Hartemink, et al.
Lung Cancer (Amsterdam, Netherlands)|December 10, 2024
The DETECTION project part 1: An international Delphi survey about diagnostics and treatment of anterior mediastinal cystic lesionsFlorit Marcuse, Daphne Dumoulin, Koen Hartemink, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2023
A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non-small Cell Lung Cancer That Is Suitable for Routine Clinical DiagnosticsKarlijn Hummelink, Renaud Tissier, Linda J W Bosch, et al.
Cell Transplantation|April 18, 2012
Feasibility of intracoronary GLP-1 eluting CellBead™ infusion in acute myocardial infarctionJaco H Houtgraaf, Renate de Jong, Kim Monkhorst, et al.
Oncoimmunology|August 27, 2024
Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL productsSuzanne M Castenmiller, Nandhini Kanagasabesan, Aurélie Guislain, et al.
Critical Reviews in Oncology/Hematology|March 8, 2022
Challenges in breast cancer genetic testing. A call for novel forms of multidisciplinary care and long-term evaluationFred H Menko, Kim Monkhorst, Frans B L Hogervorst, et al.
Oncoimmunology|December 5, 2022
<i>SERPINB9</i> is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade responseSofía Ibáñez-Molero, Alex van Vliet, Joanna Pozniak, et al.
Pageof 11

Showing results (41-50 of 103) with videos related to

Sort By:
Pageof 11
JCO Precision Oncology|October 11, 2021
Clinical Utility of Plasma-Based Comprehensive Molecular Profiling in Advanced Non-Small-Cell Lung CancerRobert D Schouten, Daan C L Vessies, Linda J W Bosch, et al.
ERJ Open Research|March 29, 2019
Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisionsKarlijn Hummelink, Mirte Muller, Theodora C Linders, et al.
Molecular Oncology|June 8, 2022
Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II-IIIA NSCLC patientsDaan C L Vessies, Milou M F Schuurbiers, Vincent van der Noort, et al.
Plos Medicine|April 15, 2025
Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: A retrospective validation studyMilou M F Schuurbiers, Christopher G Smith, Koen J Hartemink, et al.
Lung Cancer (Amsterdam, Netherlands)|December 10, 2024
The DETECTION project part 1: An international Delphi survey about diagnostics and treatment of anterior mediastinal cystic lesionsFlorit Marcuse, Daphne Dumoulin, Koen Hartemink, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2023
A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non-small Cell Lung Cancer That Is Suitable for Routine Clinical DiagnosticsKarlijn Hummelink, Renaud Tissier, Linda J W Bosch, et al.
Cell Transplantation|April 18, 2012
Feasibility of intracoronary GLP-1 eluting CellBead™ infusion in acute myocardial infarctionJaco H Houtgraaf, Renate de Jong, Kim Monkhorst, et al.
Oncoimmunology|August 27, 2024
Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL productsSuzanne M Castenmiller, Nandhini Kanagasabesan, Aurélie Guislain, et al.
Critical Reviews in Oncology/Hematology|March 8, 2022
Challenges in breast cancer genetic testing. A call for novel forms of multidisciplinary care and long-term evaluationFred H Menko, Kim Monkhorst, Frans B L Hogervorst, et al.
Oncoimmunology|December 5, 2022
<i>SERPINB9</i> is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade responseSofía Ibáñez-Molero, Alex van Vliet, Joanna Pozniak, et al.
Pageof 11